Given the remarkably high cure rates for clinical stage (CS) I testicular cancer, the toxicities and risks of adjuvant treatments, the cost effectiveness of surveillance, and the lack of reliable biomarkers to predict relapse, surveillance should be recommended for all patients with CS I testicular cancer.